Adial Pharmaceuticals Targets $40B Addiction Market

Adial Pharmaceuticals Acquires Genetic Diagnostic Tool Patent for Addiction Treatment

Adial Pharmaceuticals, a specialized biopharmaceutical company focused on addiction treatment, has announced the acquisition of a new patent for a genetic diagnostic tool that complements their lead drug candidate, AD04. This drug is used for alcohol use disorder (AUD) and potentially opioid use disorder (OUD). The patent will protect the company’s ability to use its proprietary genetic diagnostic to identify patients who may respond well to AD04 based on specific genotypes. The successful results of the ONWARD Phase 3 trial, which demonstrated significant benefits for certain genotypes, preceded this exciting development.